ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,487.03
      0.25%
      US Tech 100
      19,430.40
      0.14%
      Dow Jones
      38,834.86
      0.15%
      Brent Oil
      84.695
      -0.11%
      Bitcoin
      65,044.72
      -0.14%
      Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. AVEO Pharmaceuticals Inc (AVEO)

      7. AVEO Pharmaceuticals Inc (AVEO) News

      AVEO

      AVEO Pharmaceuticals (AVEO)

      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:AVEO
      DateTimeSourceHeadlineSymbolCompany
      05/29/20207:00AMBusiness WireAVEO Oncology Announces TIVO-3 Final Overall Survival Results Featured at ASCO 2020 Virtual Scientific Program & Submitted to...NASDAQ:AVEOAVEO Pharmaceuticals Inc
      05/27/20204:21PMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:AVEOAVEO Pharmaceuticals Inc
      05/27/20204:17PMEdgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:AVEOAVEO Pharmaceuticals Inc
      05/27/20204:05PMBusiness WireAVEO Announces Change to Virtual Annual Meeting of StockholdersNASDAQ:AVEOAVEO Pharmaceuticals Inc
      04/30/20207:05AMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:AVEOAVEO Pharmaceuticals Inc
      04/30/20207:00AMBusiness WireAVEO Oncology Reports First Quarter 2020 Financial Results and Provides Business UpdateNASDAQ:AVEOAVEO Pharmaceuticals Inc
      04/30/20206:30AMEdgar (US Regulatory)Quarterly Report (10-q)NASDAQ:AVEOAVEO Pharmaceuticals Inc
      04/29/20202:30PMBusiness WireAVEO Oncology to Present Final Overall Survival Analysis from the Phase 3 TIVO-3 Trial of Tivozanib in Renal Cell Carcinoma a...NASDAQ:AVEOAVEO Pharmaceuticals Inc
      04/28/20205:18PMEdgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:AVEOAVEO Pharmaceuticals Inc
      04/28/20205:09PMEdgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:AVEOAVEO Pharmaceuticals Inc
      04/23/20209:55AMEdgar (US Regulatory)Confidential Treatment Order (ct Order)NASDAQ:AVEOAVEO Pharmaceuticals Inc
      04/23/20209:53AMEdgar (US Regulatory)Confidential Treatment Order (ct Order)NASDAQ:AVEOAVEO Pharmaceuticals Inc
      03/31/20204:05PMBusiness WireAVEO Oncology Announces Submission of New Drug Application to U.S. FDA for Tivozanib in Patients with Relapsed or Refractory ...NASDAQ:AVEOAVEO Pharmaceuticals Inc
      03/27/20204:40PMBusiness WireAVEO Oncology & Biodesix to Discontinue CyFi-2 Study of Ficlatuzumab in Relapsed & Refractory AML in Response to Public Healt...NASDAQ:AVEOAVEO Pharmaceuticals Inc
      03/16/20204:05PMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:AVEOAVEO Pharmaceuticals Inc
      03/16/20204:05PMEdgar (US Regulatory)Annual Report (10-k)NASDAQ:AVEOAVEO Pharmaceuticals Inc
      03/16/20204:05PMBusiness WireAVEO Oncology Reports Full Year 2019 Financial Results and Provides Business UpdateNASDAQ:AVEOAVEO Pharmaceuticals Inc
      02/19/20205:11PMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:AVEOAVEO Pharmaceuticals Inc
      02/19/20209:08AMBusiness WireAVEO Announces Effectiveness of 1-for-10 Reverse Stock SplitNASDAQ:AVEOAVEO Pharmaceuticals Inc
      02/13/20204:35PMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:AVEOAVEO Pharmaceuticals Inc
      02/12/20204:26PMBusiness WireAVEO Oncology Announces Publication of Phase 1b/2 Study of Tivozanib in Advanced, Inoperable Liver Cancer in the British Jour...NASDAQ:AVEOAVEO Pharmaceuticals Inc
      01/27/20207:00AMBusiness WireAVEO Oncology & Biodesix Announce Results from Phase 1b Study of Ficlatuzumab, Gemcitabine & Nab-paclitaxel in Advanced Pancr...NASDAQ:AVEOAVEO Pharmaceuticals Inc
      01/06/20207:00AMBusiness WireAVEO Announces Appointment of Erick J. Lucera as Chief Financial OfficerNASDAQ:AVEOAVEO Pharmaceuticals Inc
      12/04/20197:00AMBusiness WireAVEO Oncology Announces Lancet Oncology Publication of Data from Phase 3 TIVO-3 Study of Tivozanib in Renal Cell CarcinomaNASDAQ:AVEOAVEO Pharmaceuticals Inc
      11/26/20197:00AMBusiness WireAVEO Oncology to Present at the 31st Annual Piper Jaffray Healthcare ConferenceNASDAQ:AVEOAVEO Pharmaceuticals Inc
      11/19/20197:00AMBusiness WireAVEO Oncology Announces Appointment of Scarlett Spring to its Board of DirectorsNASDAQ:AVEOAVEO Pharmaceuticals Inc
      11/18/20196:00AMBusiness WireAVEO Announces Presentation of Updated OS and Subgroup Data from Phase 3 TIVO-3 Trial of Tivozanib in Renal Cell CarcinomaNASDAQ:AVEOAVEO Pharmaceuticals Inc
      11/12/20197:16AMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:AVEOAVEO Pharmaceuticals Inc
      11/12/20197:15AMEdgar (US Regulatory)Quarterly Report (10-q)NASDAQ:AVEOAVEO Pharmaceuticals Inc
      11/12/20197:00AMBusiness WireAVEO Reports Third Quarter 2019 Financial Results and Provides Business UpdateNASDAQ:AVEOAVEO Pharmaceuticals Inc
       Showing the most relevant articles for your search:NASDAQ:AVEO